June 2020
Volume 61, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2020
Effects of Glycyrrhizin on Multi-Drug Resistant Pseudomonas aeruginosa.
Author Affiliations & Notes
  • Linda D Hazlett
    Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, Michigan, United States
  • Sharon McClellan
    Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, Michigan, United States
  • Mallika Somayajulu
    Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, Michigan, United States
  • Ahalya Pitchaikannu
    Ophthalmology, Visual and Anatomical Sciences, Wayne State University, Detroit, Michigan, United States
  • Nicholas Carruthers
    Proteomics Core, Wayne State University, Detroit, Michigan, United States
  • Paul Stemmer
    Proteomics Core, Wayne State University, Detroit, Michigan, United States
  • Footnotes
    Commercial Relationships   Linda Hazlett, None; Sharon McClellan, None; Mallika Somayajulu, None; Ahalya Pitchaikannu, None; Nicholas Carruthers, None; Paul Stemmer, None
  • Footnotes
    Support  NIH R01EY016058, P30 EY004068 (both LDH) Research to Prevent Blindness (Kresge Eye Institute, Detroit MI), P30ES020957, P30 CA022453and S10OD010700 (Proteomics Core)
Investigative Ophthalmology & Visual Science June 2020, Vol.61, 453. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Linda D Hazlett, Sharon McClellan, Mallika Somayajulu, Ahalya Pitchaikannu, Nicholas Carruthers, Paul Stemmer; Effects of Glycyrrhizin on Multi-Drug Resistant Pseudomonas aeruginosa.. Invest. Ophthalmol. Vis. Sci. 2020;61(7):453.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To determine the effects of glycyrrhizin (GLY) on virulence factors of multi-drug resistant systemic (MDR9) vs ocular (B1045) clinical isolates.

Methods : Isolates were grown in 25ml of PTSB at 37oC for 18h and proteomes profiled using LC-MS/MS with label free quantitation by the WSU Proteomics Core. Mining factors included genes and proteins: Virulence and Quorum sensing (toxA, exoS, plcH, plcN, lasB, hcnC, aroE, rpoN, ccmg, sodB, phzS, 6cl5, lasI, lasR, rhlR); Antibiotic resistance (ampC, mexC); Biofilms-exopolysaccharides, proteins and proteinaceous surface appendages; adherence (pslA, pslB, pslC, pslD, pslE, pslF, pslG, pslH, pslI, pslJ, pslK, pslL, pslM, pslN, pslO, pelA, pelB, pelC, pelD, pelE, pelF, GacA, RetS, LadS, algL,T4P, CdrA, CupA, CupB, CupC, CupE, HptB, T3SS, T6SS).
Also, transfected human (HCET) and mouse (MCEC) corneal epithelial cells were seeded onto chambered slides and incubated overnight. Cell chambers were washed and media added without antibiotics. Each isolate was combined with GLY (0, 5 and 10 mg/mL) before application to the slides (10 MOI/cell). After 3 hr (37°C, aerobic conditions), slides were washed, stained (Wright-Giemsa), air dried, and cover slipped. Bacteria adherent to cells (n=100/group) were photographed, counted, averaged, and expressed as number bacteria/cell. Biofilm was tested by a colorimetric microtiter plate assay.

Results : 3,254 proteins were identified and 3,211 were quantified. Using a cutoff of 0.1 for false-discovery corrected p-values, 1,355 proteins were different between GLY treated vs untreated MDR9 and 5 between GLY treated vs untreated B1045. In MDR9 almost half of the proteome was affected whereas B1045 was minimally affected. Principal component analysis and hierarchical clustering distinguished treated from untreated MDR9 samples but yielded mixed results for B1045. However, GLY prevented adherence to both groups of cells and decreased biofilm.

Conclusions : GLY had a greater effect on MDR9 vs B1045 at the proteomic level, but was similar for each at disrupting adherence, the first step in biofilm formation.

This is a 2020 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×